Strategic Growth Sanofi US is actively expanding its footprint in the United States (Morristown, NJ) and pursuing significant investments in China (Beijing insulin production base). Opportunities exist for partnerships or local supply-chain optimization, manufacturing enablement, and regional R&D collaborations to support scale and diversification of production.

Therapeutic Focus Core areas include cardiovascular disease, oncology, diabetes, CNS, vaccines, and internal medicine with a notable emphasis on insulin production capacity. Sales prospects include supply agreements, device integration for clinical workflows, and analytics or real-world evidence solutions to support product launches and lifecycle management.

Regulatory Actions Recent patent litigation activity around mRNA technologies and historical compliance concerns highlight a need for robust risk management, IP diligence services, and potential advisory offerings for regulatory and payer strategy, contract hygiene, and anti-fraud controls in collaboration ecosystems.

Healthcare Innovation Strategic partnerships in radioligand therapies with Orano Med and RadioMedix indicate ongoing R&D expansion in rare cancers and advanced therapies. Potential for BD opportunities in translational research services, clinical trial operations support, and lab automation or data integration platforms to accelerate development.

Digital & Ops Enablement Existing tech stack includes Aravo, Epic Systems, cloud infrastructure, and lab automation. Potential sales angles include procurement governance improvements, EHR/clinical data integration, manufacturing analytics, and cloud-based compliance or monitoring solutions to optimize supply, quality, and operational efficiency.